Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMDOCE-BU
NCT07322263Phase 2Recruiting
- Start
- Apr 2026
- Primary completion
- Jan 2033
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, docetaxel in non-muscle-invasive bladder cancer (NMIBC). Started Apr 2026; status: recruiting.
02
Drugs
gemcitabinedocetaxel
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT07322263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07322263.